What is the Historical Analysis of the Muscarinic Acetylcholine Receptor Market Size?
The muscarinic acetylcholine receptor market has seen considerable growth due to a variety of factors.
•The market size of the muscarinic acetylcholine receptor has witnessed stable growth in the past few years. The market is projected to expand from $1.82 billion in 2024 to $1.89 billion in 2025, registering a compound annual growth rate (CAGR) of 4.2%.
The growth experienced in the past years is the result of treatments for neurological disorders, the handling of cardiovascular disorders, therapy for ophthalmic disorders, respiratory conditions treatment, and gastrointestinal disorders.
What is the Forecasted Growth of the Muscarinic Acetylcholine Receptor Market Size?
The muscarinic acetylcholine receptor market is expected to maintain its strong growth trajectory in upcoming years.
• Expect robust expansion in the muscarinic acetylcholine receptor market in the coming years, with its value projected to reach "$2.37 billion in 2029 at a CAGR of 5.8%.
Factors contributing to this growth during the forecast period are progress in neuropharmacology, a rise in cardiovascular disease instances, advances in ophthalmic treatments, the introduction of new respiratory therapies, and a growing gastrointestinal drug portfolio. Noteworthy trends in the forecast period encompass its application in eye-related conditions, tactical collaborations for drug discovery, creation of tissue-selective agents, its potential in treating gastrointestinal disorders, and emphasis on individualized treatment strategies.
What Are The Primary Growth Drivers In The Muscarinic Acetylcholine Receptor Market?
The growth of the muscarinic acetylcholine receptor market is predicted to be fueled by the rising incidence of neurological disorders. These disorders are medical conditions impacting the nervous system, which encapsulates the brain, spinal cord, and peripheral nerves. Muscarinic acetylcholine receptors (mAChR), which regulate complex behaviors like cognition, locomotion, and reward, are invaluable as therapeutic targets for various neurological diseases. For example, data from the Australian Bureau of Statistics National Health Survey revealed in December 2023 that the prevalence of heart disease and stroke in Australia had risen to 5.2%, affecting 1.3 million people in 2022. This was a significant increase from 4.1% in 2001. Hence, the escalating incidence of neurological disorders is a major factor propelling the growth of the muscarinic acetylcholine receptor market.
What Is The Segmentation Of The Global Muscarinic Acetylcholine Receptor Market?
The muscarinic acetylcholine receptor market covered in this report is segmented –
1) By Type: M1, M4, M5, Other Types
2) By Distribution Channel: Hospitals, Clinics, Retail Pharmacies, Online Pharmacies, Specialty Centers
3) By Application: Chronic Obstructive Pulmonary Disease, Attention Deficit Hyperactivity Disorder, Alzheimer's Disease, Memory Impairment, Psychiatric Disorders, Other Applications
Subsegments:
1) By M1 Receptor: Centrally Acting Antagonists, Centrally Acting Agonists, Peripherally Acting Compounds
2) By M4 Receptor: Selective Agonists, Selective Antagonists, Non-Selective Agents
3) By M5 Receptor: Agonists, Antagonists, Other Modulators
4) By Other Types: M2 Receptor, M3 Receptor, Combination Receptor Products
Pre-Book The Muscarinic Acetylcholine Receptor Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The Muscarinic Acetylcholine Receptor Market Landscape?
The surge in research and development initiatives is becoming a significant trend in the muscarinic acetylcholine receptor market. Firms in this market are embracing new undertakings to maintain their market presence. For instance, in January 2022, research conducted by Wenping Li under Merck, a German-based science and technology firm, resulted in the MK-6884 molecule. This molecule, labelled with carbon-11, can detect the M4 subtype of muscarinic cholinergic receptors. MK-6884 paves the way for researchers to gauge the effectiveness of cholinergic drugs and the loss of acetylcholine receptors in neurodegenerative conditions such as Alzheimer's disease, amongst others.
Who Are the Key Players in the Muscarinic Acetylcholine Receptor Market?
Major companies operating in the muscarinic acetylcholine receptor market include:
• Heptares Therapeutics Ltd.
• Sumitomo Dainippon Pharma Co. Ltd.
• Anavex Life Sciences Corp.
• NeuroHealing Pharmaceuticals Inc.
• AstraZeneca plc
• Karuna Pharmaceuticals Inc.
• Anven AlzDx Inc.
• Merck & Co Inc.
• Elsevier BV
• Eurofins Discover X Corporation
• Novus Biologicals LLC
• Eli Lilly and Co.
• Novatein Biosciences Inc.
• Alomone Labs Ltd.
• GlaxoSmithKline plc
• SK Bioscience Co.
• Johnson & Johnson
• Pfizer Inc.
• Novartis AG
• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• F. Hoffmann-La Roche Ltd.
• Eisai Co. Ltd.
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
What are the Regional Insights into the Muscarinic Acetylcholine Receptor Market?
North America was the largest region in the muscarinic acetylcholine receptor market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global muscarinic acetylcholine receptor market during the forecast period. The regions covered in the muscarinic acetylcholine receptor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
